Showing 1 - 5 of 5 Movement Disorders

Status: Enrolling

Investigator: William Ondo

Study Coordinator: Chelsea Kinney

Phone: 346.238.9068

The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD. ... Read more >

Status: Enrolling

Investigator: Tetsuo Ashizawa

Study Coordinator:

Phone:

The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with spinocerebellar ataxia (SCA). ... Read more >

Status: Enrolling

Investigator: Olga Waln

Study Coordinator: Yvonne Subhan

Phone: 346.238.9068

This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease. ... Read more >

Status: Enrolling

Investigator: Tetsuo Ashizawa

Study Coordinator:

Phone:

Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCA and this study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known ... Read more >

Status: Enrolling

Investigator: Olga Waln

Study Coordinator:

Phone:

The purpose of this study is to determine whether a single treatment with administration of NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of essential tremor in the arm (Unilateral Period). Participants wi ... Read more >